The American Journal of Medicine
Volume 121, Issue 3 , Pages 231-238 , March 2008

Activated Partial Thromboplastin Time and Risk of Future Venous Thromboembolism

  • Neil A. Zakai, MD

      Affiliations

    • Department of Medicine, Brown University and Boston University, Providence, RI
    • Department of Medicine, University of Vermont, Burlington.
    • ,
  • Tetsuya Ohira, MD, PhD

      Affiliations

    • Division of Epidemiology and Community Health, University of Minnesota, Minn
    • Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka Medical Center, Osaka, Japan
    • ,
  • Richard White, MD

      Affiliations

    • Department of Medicine, University of California Davis Medical Center, Sacramento
    • ,
  • Aaron R. Folsom, MD

      Affiliations

    • Division of Epidemiology and Community Health, University of Minnesota, Minn
    • ,
  • Mary Cushman, MD, MSc

      Affiliations

    • Department of Medicine, University of Vermont, Burlington.
    • Corresponding Author InformationRequests for reprints should be addressed to Mary Cushman, MD, MSc, University of Vermont, 208 South Park Drive, Suite 2, Colchester, VT 05446.

References 

  1. White GC. The partial thromboplastin time: defining an era in coagulation. J Thromb Haemost. 2003;1:2267–2270
  2. Aboud MR, Ma DD. Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance. Clin Lab Haematol. 2001;23:411–416
  3. Tripodi A, Chantarangkul V, Martinelli I, et al. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood. 2004;104:3631–3634
  4. Hron G, Eichinger S, Weltermann A, et al. Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost. 2006;4:752–756
  5. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517–522
  6. Bank I, Libourel EJ, Middeldorp S, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost. 2005;3:79–84
  7. Begbie M, Notley C, Tinlin S, et al. The Factor VIII acute phase response requires the participation of NFkappaB and C/EBP. Thromb Haemost. 2000;84:216–222
  8. Makris M, Colvin B, Gupta V, et al. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease. [see comment] Thromb Haemost. 2002;88:387–388
  9. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the Longitudinal Investigation of Thromboembolism Etiology. Am J Med. 2004;117:19–25
  10. The Atherosclerosis Risk in Communities (ARIC) Study (Design and objectives. The ARIC investigators). Am J Epidemiol. 1989;129:687–702
  11. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263–276
  12. Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). [see comment] Am J Med. 2002;113:636–642
  13. Folsom AR, Wu KK, Rosamond WD, et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997;96:1102–1108
  14. Chambless LE, McMahon R, Wu K, et al. Short-term intraindividual variability in hemostasis factors. The ARIC Study. Atherosclerosis Risk in Communities Intraindividual Variability Study. Ann Epidemiol. 1992;2:723–733
  15. Cushman M, Folsom AR, Wang L, et al. Fibrin fragment D-dimer and the risk of future venous thrombosis. [see comment] Blood. 2003;101:1243–1248
  16. Wilcosky TC, Chambless LE. A comparison of direct adjustment and regression adjustment of epidemiologic measures. J Chronic Dis. 1985;38:849–856
  17. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis (The Atherosclerosis Risk in Communities (ARIC) Study). [see comment] Thromb Haemost. 1993;70:380–385
  18. Phillips AN, Smith GD. How independent are “independent” effects? (Relative risk estimation when correlated exposures are measured imprecisely). J Clin Epidemiol. 1991;44:1223–1231
  19. Tripodi A. Levels of coagulation factors and venous thromboembolism. Haematologica. 2003;88:705–711
  20. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med. 2005;118:978–980
  21. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003;89:493–498

 Atherosclerosis Risk in Communities is supported by contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC 55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022, with additional support from R01-HL-59367, all from the National Heart, Lung, and Blood Institute.

PII: S0002-9343(07)01096-0

doi: 10.1016/j.amjmed.2007.10.025

The American Journal of Medicine
Volume 121, Issue 3 , Pages 231-238 , March 2008

Article Tools

* Image Usage & Resolution